| Unique ID issued by UMIN | UMIN000062399 |
|---|---|
| Receipt number | R000071416 |
| Scientific Title | Functional evaluation of mycoproteins (Gut microbiota) |
| Date of disclosure of the study information | 2026/07/30 |
| Last modified on | 2026/07/30 10:58:23 |
Functional evaluation of mycoproteins (Gut microbiota)
Functional evaluation of mycoproteins (Gut microbiota)
Functional evaluation of mycoproteins (Gut microbiota)
Functional evaluation of mycoproteins (Gut microbiota)
| Japan |
Healthy adults
| Not applicable | Adult |
Others
NO
Exploratory evaluation of the effects of 6-week mycoprotein consumption on the gut environment.
Safety,Efficacy
Changes in gut microbiota before and after the intervention
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
| Food |
Intake of test food for 6 weeks
| 30 | years-old | <= |
| 60 | years-old | > |
Male and Female
1.Subjects aged 30 to 60 at the time of obtaining consent
2.Subjects receiving a sufficient briefing of the objective and content of the present study, fully understanding and agreeing to voluntarily participate in the study and being able to personally sign a written informed consent
3.Subjects who have not taken any foods for specified health uses, functional foods, dietary supplements, that may affect defecation, or who can maintain the same type and frequency of intake of these products they have been taking up until that point during the study period
1.Subjects with serious cardiovascular, hepatic, renal, respiratory, endocrine or metabolic disorders or having a medical history of these disorders (Including those taking medications for the treatment or management of conditions such as diabetes, dyslipidemia, or hypertension)
2.Subjects receiving treatment for a gastrointestinal disease currently or those who have had gastrointestinal surgery
3.Subjects with an allergy to the test food
4.Subjects who are suffering from or have a history of a disease that may affect defecation
5.Subjects who take regularly pharmaceuticals or quasi-drugs having the efficacy for microbiome such as intestinal regulator
6.Subjects who have used antibiotics within the past month, or who plan to use them during the study period
7.Subjects who plan to make significant changes to their lifestyle (e.g., diet, sleep, exercise) during the study period
8.Female subjects who are pregnant or lactating, or intending to become pregnant during the study
9.Subjects who took part in another study within 3 months prior to the start of the present study or who are currently taking part in another study
10. Subjects deemed unsuitable by the investigator
30
| 1st name | Kiyotaka |
| Middle name | |
| Last name | Sugiyama |
Agro Ludens Inc.
Representative Director
100-0006
2-10-1 Yurakucho, Chiyoda-ku
03-5832-9453
k.saga@agroludens.com
| 1st name | Takayoshi |
| Middle name | |
| Last name | Fukushima |
Cykinso, Inc.
BtoB Division
151-0053
1-36-1 Yoyogi, Shibuya-ku
03-5309-2522
mykinsoresearch_mq04@cykinso.co.jp
Agro Ludens Inc.
Agro Ludens Inc.
Profit organization
Shiba Palace Clinic Ethics Review Committee
DaiwaA Hamamatsucho Bldg. 6F, 1-9-10, Hamamatsucho, Minato-ku
03-5408-1599
shiba_palace@s-palace-clinic.com
NO
| 2026 | Year | 07 | Month | 30 | Day |
Unpublished
Preinitiation
| 2026 | Year | 07 | Month | 23 | Day |
| 2026 | Year | 07 | Month | 23 | Day |
| 2026 | Year | 08 | Month | 31 | Day |
| 2026 | Year | 10 | Month | 09 | Day |
| 2026 | Year | 07 | Month | 30 | Day |
| 2026 | Year | 07 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071416